NF2 and renal cell carcinoma: Recently, a RCC with NF2 genomic alteration (GA) gained attention not only due to morphologic features6,7 but also due to its association with treatment responses in nccRCC.6 In a recent phase II clinical trial of advanced nccRCC, 5 of 6 patients with NF2 mutations achieved an objective response to multi-targeted tyrosine kinase inhibitor cabozantinib plus human programmed death receptor-1 (PD-1) blocker nivolumab.8